Construction started on US-based life science outsourcing company BioDuro's China Innovation Drug Research and Development Center in Huishan district, Wuxi on April 17.
BioDuro invested $180 million in the center, which will be the largest R&D center in Wuxi and house a 30,000-square-meter industrial port GMP plant. It will work to combine the outsourcing of biomedical services with the research and development of drugs, aiming to make it easier for pharmaceutical companies to launch new products.
In addition, the R&D center will work to incubate a number of top biotech innovation teams and projects in order to build a complete industrial chain for the development and production of innovative drugs in China.
BioDuro is a US provider of medical contract research, development, and manufacturing outsourcing solutions. In recent years, its revenue has continued to grow by more than 30 percent per year, making it the world's leading clinical research organization (CRO).
The company has been working to provide support for GHDDI, a global drug research and development center, and participate in molecular chemical synthesis and drug design targeting protein production amid the COVID-19 epidemic.
The company also helped in the application of emergency and prevention systems and technology organized by the Wuxi Science and Technology Bureau with its project on the development of nano antibody drugs for treating the novel coronavirus.
